ArcherDX Launches FusionPlex™ Lung Thyroid and FusionPlex™ Solid Tumor Panels

BOULDER, Colo.--()--Today ArcherDX expanded its Archer™ FusionPlex™ assay menu to include the FusionPlex Lung Thyroid Panel and FusionPlex Solid Tumor Panel. The two panels are targeted next generation sequencing (NGS)-based assays that can be used to detect gene translocations in clinical samples types. The Lung Thyroid Panel simultaneously detects and characterizes fusions of 8 genes associated with NSCLC and thyroid cancer. The Solid Tumor Panel is the company’s largest catalog gene panel to date, detecting and identifying fusions and other mutations associated with over 50 different genes linked to carcinomas and solid tumors. The FusionPlex Solid Tumor Panel rounds out the company’s tumor fusion offering, complementing existing Heme and Sarcoma fusion panels to provide pan-cancer coverage of gene translocations.

Both panels enable detection of fusions associated with the genes in the panel in a single sequencing assay, even without prior knowledge of fusion partners or breakpoints. “With the launch of these two assays, Archer has established itself as the clear leader in NGS-based fusion detection. With the FusionPlex Lung Thyroid Panel, we now offer robust fusion detection for the cancer with the highest mortality rate as well as the one with the highest growing incidence rate. And with the FusionPlex Solid Tumor Panel coupled with our complimentary Archer Analysis bioinformatics software, we now offer the most comprehensive fusion detection system,” says Jeff Mitchell, Product Manager at ArcherDX.

About Archer FusionPlex NGS Assays

The Archer FusionPlex Assays generate target-enriched cDNA libraries for NGS-based gene fusion detection. The system leverages Anchored Multiplex PCR (AMP™) to selectively amplify cDNAs of specific genes of interest in a sample along with any fusion partners, known or unknown. The FusionPlex system uses random start sites to improve sequence data quality and novel enrichment chemistry to yield a high on-target percentage

FusionPlex assays are part of Archer’s targeted NGS mutation detection workflow that includes library preparation, analysis and reporting. Archer assays use a simple lyophilized workflow optimized to minimize hands-on time and risk of contamination in library preparation, making them ideal for high-volume laboratories. The AMP-enabled FusionPlex panels are target enrichment assays used to create libraries for Illumina® or Ion Torrent™ sequencing from small amounts (5-200 ng) of nucleic acid extracted from formalin-fixed, paraffin-embedded (FFPE) clinical samples. Once sequenced, the Archer Analysis software provides comprehensive analysis with embedded QC metrics and read visualization to accurately detect and identify known and novel fusions, SNPs, indels and CNVs.

About ArcherDX

ArcherDX addresses the bottlenecks associated with using next-generation sequencing in translational research by offering a robust platform for targeted sequencing applications. Combining Anchored Multiplexed PCR (AMP) and easy-to-use, lyophilized reagents, our technology generates a highly enriched library of gene targets of interest for downstream genomic sequencing.

Complemented by the Archer™ suite of bioinformatics software and readily accessible reports, AMP technology enables dramatic enhancement in mutation detection speed as well as complex mutation identification and discovery. ArcherDX offers FusionPlex panels to detect ALK, RET, ROS1, FGFR and NTRK fusions and those associated with sarcomas and hematological malignancies.

ArcherDX is headquartered in Boulder, Colo., and maintains manufacturing operations in Beverly, Mass.

Note: Archer kits and analysis software are for research use only and not for use in diagnostic procedures.


ArcherDX, Inc.
Jason Amsbaugh, +1 303-357-9001

Release Summary

ArcherDX launches new FusionPlex panels to detect gene fusions and other mutations by NGS. The Lung Thyroid Panel targets lung and thyroid cancers, and the Solid Tumor Panel aims at carcinomas.

ArcherDX, Inc.